Perrigo parts with Elan Alzheimer's inheritance
This article was originally published in Scrip
Executive Summary
Dublin, Ireland-headquartered Perrigo has sold off all rights to an Alzheimer's compound it inherited from Elan following a controversial acquisition of the company for $8.6bn last year.